REGENXBIO Inc.

RGNXNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
9.38 USD
↗ 0.47 (5.28%)AT CLOSE (11:59 AM EDT)
9.25
↘ 0.14 (1.44%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
9.25
↘ 0.14 (1.44%)
🔴Market: CLOSED

RGNX is currently priced at $9.39. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On valuation, RGNX trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Aug 26, 2026.

Open?$8.85
High?$9.43
Low?$8.61
Prev. Close?$8.91
Volume?1.2M
Avg. Volume?1.6M
VWAP?$9.17
Rel. Volume?0.74x
Bid / Ask
Bid?$9.02 × 2.0K
Ask?$9.38 × 800
Spread?$0.36
Midpoint?$9.20
Valuation & Ratios
Market Cap?619.2M
Shares Out?66.0M
Float?39.6M
Float %?76.5%
P/E Ratio?N/A
P/B Ratio?8.63
EPS?-$2.98
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
371
Market Cap
588.2M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.regenxbio.com
Listed
2015-09-17
Address
9804 MEDICAL CENTER DRIVE
ROCKVILLE, MD 20850
Phone: 240-552-8181
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
0
Momentum?
62
Short Sent.?
20
Piotroski F-Score?4/9Mixed
Altman Z-Score?-3.61Distress
Confidence?58%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?20.72%Squeeze Risk
Short Interest?8.2M
Days to Cover?7.8
Free Float39.6M
Avg Daily Volume1.1M
Settlement Date2026-08-14
Financial Health
Current Ratio?2.86Strong
Quick Ratio?2.86Strong
Cash Ratio?0.44Low
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
22
8.63HIGH▾
P/S?
Peers
100
S&P
43
3.55FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.9CHEAP▾
EV/Sales?
Peers
100
S&P
56
3.34FAIR▾
Returns & Efficiency
ROE?
S&P
3
-273.7%WEAK▾
ROA?
S&P
3
-50.8%WEAK▾
Cash Flow & Enterprise
FCF?$-249668000
Enterprise Value?$582.7M
Fundamentals ratios updated end of day
MarketsMoversWatchlist